LB 882 would take cancer treatment decisions away from insurance companies and put them back into the hands of patients and their doctors.
That’s according to Omaha Senator Jeremy Nordquist, who introduced LB 882. He says the measure creates parity between oral chemotherapy medications and IV medications for cancer patients. Senator Nordquist says under the current system, IV medications are considered a medical benefit.